Nagai Yuko, Obata Sho, Kawashima Kayoko, Kawabe Takanari, Hanada Yukiko, Yamaguchi Tomohiro, Ueno Rumi, Tsurinaga Yuki, Fukasawa Youhei, Takaoka Yuri, Yoshida Yukinori, Kameda Makoto
Osaka Habikino Medical Center - Otorhinolaryngology/Head and Neck Surgery, Osaka, Japan.
Osaka Habikino Medical Center - Otorhinolaryngology/Head and Neck Surgery, Osaka, Japan.
Auris Nasus Larynx. 2025 Oct;52(5):610-614. doi: 10.1016/j.anl.2025.08.002. Epub 2025 Sep 8.
To investigate whether sublingual immunotherapy (SLIT) with house dust mite (HDM) extract suppresses new sensitization to Japanese cedar pollen(JCP) in children with HDM-positive allergic rhinitis.
This retrospective study was conducted at our center and included pediatric patients aged 5-15 years who visited between January 2018 and December 2020. Eligible patients tested positive for HDM-specific immunoglobulin E (IgE), negative for JCP-specific IgE, and had no history of SLIT for cedar pollen. 33 patients who continued HDM SLIT for 3 years were assigned to the SLIT group, while 52 patients with allergic rhinitis who did not receive HDM SLIT formed the non-SLIT group. Patients with severe allergic comorbidities or those undergoing immunosuppressive therapy were excluded. The primary endpoints were the rate of new sensitization to Japanese cedar pollen and the cedar-specific IgE levels after 3 years. We used the chi-square test, t-test, Mann-Whitney U test, and logistic regression analysis to compare the groups.
After 3 years, the rate of new sensitization to JCP was 42.4 % in the SLIT group and 51.9 % in the non-SLIT group (p = 0.383). The JCP-specific IgE level was 4.77 UA/mL in the SLIT group and 7.93 UA/mL in the non-SLIT group (p = 0.207).
The SLIT group showed a slightly lower rate of new sensitization and lower JCP-specific IgE levels; however, the differences were not statistically significant. A larger, multi-center study is needed to confirm these findings and adjust for potential confounders.
探讨屋尘螨(HDM)提取物舌下免疫治疗(SLIT)是否能抑制HDM阳性变应性鼻炎儿童对日本雪松花粉(JCP)的新致敏。
本回顾性研究在我们中心进行,纳入了2018年1月至2020年12月期间就诊的5-15岁儿科患者。符合条件的患者HDM特异性免疫球蛋白E(IgE)检测呈阳性,JCP特异性IgE检测呈阴性,且无雪松花粉SLIT治疗史。33例持续进行HDM SLIT治疗3年的患者被分配到SLIT组,而52例未接受HDM SLIT治疗的变应性鼻炎患者组成非SLIT组。排除有严重过敏性合并症或正在接受免疫抑制治疗的患者。主要终点是3年后对日本雪松花粉的新致敏率和雪松特异性IgE水平。我们使用卡方检验、t检验、曼-惠特尼U检验和逻辑回归分析来比较各组。
3年后,SLIT组对JCP的新致敏率为42.4%,非SLIT组为51.9%(p = 0.383)。SLIT组JCP特异性IgE水平为4.77 UA/mL,非SLIT组为7.93 UA/mL(p = 0.207)。
SLIT组的新致敏率略低,JCP特异性IgE水平也较低;然而,差异无统计学意义。需要进行更大规模的多中心研究来证实这些发现并调整潜在的混杂因素。